



Identification Number: FDA/CSD/CPE/PRS/21/009 TYPE OF COMMUNICATION: COVID-19 VACCINE SAFETY

27th August 2021

JOINT COVID-19 VACCINE SAFETY REVIEW COMMITTEE-SAFETY MONITORING

UPDATE 9

The Food and Drugs Authority (FDA) continues to review safety reports received from the general public and healthcare professionals for all COVID-19 vaccines deployed so far and has not identified any safety concerns from the vaccinations.

As of 20th August 2021, three vaccines namely, Covishield (AstraZeneca vaccine), Sputnik V and COVID-19 Vaccine Janssen (Johnson and Johnson vaccine) have been deployed in Ghana to combat the pandemic. The total doses of the three vaccines administered is 1,404,463 consisting of 1,232,876 doses of Covishield, 107,766 doses of COVID-19 Vaccine Janssen and 63,821 doses of Sputnik V.

The most commonly reported side effects for the three vaccines were headache, fever, chills, pain at injection site and body pains which resolved within a day or two.

The FDA's Joint COVID-19 Vaccine Safety Review Committee (JCVSRC) reviewed all safety reports received from the vaccinations in Ghana and from international sources at its 10th meeting held on Friday, 20th August 2021.

The JCVSRC recommends the continued use of all COVID-19 vaccines granted Emergency Use Authorization by the FDA because they continue to be effective in reducing the risk of severe disease, hospitalization and death from coronavirus disease.

The FDA will continue to proactively monitor the safety of all vaccines issued with Emergency Use Authorization to be deployed during the pandemic.



**DELESE A. A. DARKO (MRS)
CHIEF EXECUTIVE OFFICER**